Regarding to a scholarly study published in the Journal of Scientific Investigation today*.

When drugs made to block AKT were given to mice with tumours and lab-grown malignancy cells lacking p53, the radiotherapy killed even more tumour cells. Significantly, lower activity in these genes was also associated with poorer survival in sufferers with a number of different cancers. This suggests that adding AKT inhibitors to radiotherapy could possibly be an effective method to take care of many cancers. Study leader Dr. Ester Hammond, a Cancer Study UK scientist at the University of Oxford, said, 'this exciting discovery sheds light on the part of oxygen starvation in cancer development and shows that drugs already becoming trialled in cancer patients may potentially boost the effectiveness of radiotherapy across a range of cancers.

About 32 % of 22 treatment-resistant depressed patients infused with ASD6765 showed a clinically meaningful antidepressant response at 80 minutes after infusion that lasted for approximately around 30 minutes – with residual antidepressant results lasting two days for some. By contrast, 52 % of patients receiving ketamine show a comparable response, with effects still detectable at seven days. So a single infusion of ketamine generates more robust and sustained improvement, but most individuals continue to encounter some symptoms with both medications.About 32 % of 22 treatment-resistant depressed patients infused with ASD6765 showed a clinically meaningful antidepressant response at 80 minutes after infusion that lasted for approximately around 30 minutes – with residual antidepressant results lasting two days for some. By contrast, 52 % of patients receiving ketamine show a comparable response, with effects still detectable at seven days. So a single infusion of ketamine generates more robust and sustained improvement, but most individuals continue to encounter some symptoms with both medications.